Please login to the form below

Not currently logged in
Email:
Password:

Jacques Dumas joins Nosopharm scientific advisory board

French biotech's appointments also include Dominique Breilh

Nosopharm has appointed Jacques Dumas and three others to its scientific advisory board to strengthen its preclinical development programme.

Dumas, who has over 20 years of experience of antibiotic R&D, has previously held positions as chief scientific officer at Idenix Pharmaceuticals and VP and head of strategy for AstraZeneca infectious diseases unit.

He is joined on Nosopharm's scientific advisory board by Dominique Breilh, Jean-Michel Molina and Patrice Nordmann.

Dominique Breilh runs the pharmacokinetics and clinical pharmacy laboratory at the University of Bordeaux, France; Jean-Michel Molina is professor of infectious diseases at the University of Paris Diderot; and Patrice Nordmann is professor and director of the molecular microbiology unit at Switzerland's University of Fribourg.

French biotech company Nosopharm, which focus on anti-infective research, said the four appointments reflect a new phase of development for Odilorhabdins, a novel class of antibiotics it is developing.

Philippe Villain-Guillot, CEO of Nosopharm, said: “Dominique Breilh, Jacques Dumas, Jean-Michel Molina and Patrice Nordmann have internationally renowned skills and knowledge, which is a major asset for Nosopharm.

“Their appointments reflect our desire to ramp up our development. Our aim is to run phase I clinical trials starting in 2017 to evaluate a first-generation Odilorhabdin derived from out NOSO-95 molecule.”

19th November 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics